FDA Brief

Warning letters Drugs

FDA warning letter to

Shiva Analyticals Private Limited

High riskIssued Jul 23, 2025Posted Jul 29, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Shiva Analyticals, an Indian contract drug testing lab, that inadequate OOS investigations and data integrity failures adulterated tested drugs.

What happened

FDA inspected the contract testing laboratory in Hoskote, India, from January 20 to 24, 2025. Investigators found inadequate investigations of out-of-specification results and human-error CAPA, plus many torn or discarded original CGMP documents, including balance and pH printouts; some balance printouts showed test weights different from documented testing. FDA also found hundreds of MassLynx audit-trail entries allowing peak changes and file alterations from January 2022 through January 2025.

What FDA found

  1. The firm did not thoroughly investigate out-of-specification results or unexplained discrepancies, and it used new test results to invalidate OOS results without an adequate root-cause investigation.

    21 CFR 211.192
  2. The firm did not take effective corrective and preventive action for recurring human errors that drove many laboratory incidents and OOS investigations over three years.

    21 CFR 211.192
  3. The quality control unit failed to establish or follow adequate written responsibilities and procedures to ensure reliable analytical testing data.

    21 CFR 211.22(d)
  4. FDA found many torn and discarded original CGMP documents, including analytical balance printouts, pH meter printouts, and method verification records, in the main waste area.

    21 CFR 211.22(d)
  5. Discarded balance printouts contained test weights different from those documented in testing of raw materials and finished products, including products intended for the U.S. market.

    21 CFR 211.22(d)
  6. MassLynx audit trails showed hundreds of entries allowing analysts to add, modify, or delete peaks and alter existing files from January 2022 to January 2025.

    21 CFR 211.22(d)

What FDA wants

FDA tells Shiva to promptly correct the violations and respond in writing within 15 working days with a retrospective independent review of all OOS and laboratory incident investigations, independent assessments of its investigation, quality-control, documentation, and laboratory systems, and detailed remediation plans. FDA also recommends engaging a qualified CGMP consultant.

Who should pay attention

  • drug manufacturers that use Shiva as a contract testing laboratory
  • application sponsors relying on Shiva's analytical data
  • brands and suppliers whose products were tested at this site

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk